Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (1668)	4/26/1998 6:13:00 PM
From: Ibexx	Read Replies (2) \| Respond to of 9523

brian, VVUS tanked from the $40 to a single digit in a jiffy, and it's hard for me to see you making any profit unless you were short the stock. I vaguely remember you recommend it at the high $30s or low $40s. If SI archive shows my memories are wrong, you can have my apologies. Regards, Ibexx

To: Brian Malloy who wrote (1668)	4/26/1998 7:10:00 PM
From: BigKNY3	Read Replies (2) \| Respond to of 9523

In this month's Journal of Urology, there are several abstracts of studies and analyzes that will be presented at the AUA meeting in June. Here is one Pfizer-sponsored analysis confirming Viagra's efficacy and safety in patients with severe ED. BigKNY3 Journal of Urology #910 META-ANALYSIS OF THE EFFICACY OF SILDENAFIL (VIAGRA) IN THE TREATMENT OF SEVERE ERECTILE DYSFUNCTION. William D. Steers, Charlottesville, VA; and the Sildenafil Study Group (Presented by Dr. Steers). INTRODUCTION AND OBJECTIVES: Previous studies have indicated that sildenafil is an effective and well-tolerated oral treatment for erectile dysfunction (ED) associated with a broad range of etiologies. This meta-analysis was performed to assess the efficacy of sildenafil in a subgroup of men with severe ED. METHODS: for this meta-analysis, data for 3361 patients with ED (organic 60%, psychogenic 15%, mixed 25%) from 10 double-blind, placebo-controlled, fixed-dose studies of sildenafil (50-100mg) were merged. Sildenafil or placebo was taken as needed 1 hour prior to sexual activity for 8 weeks. The frequency of penetration (Q3) and the frequency of maintained erections (Q4) were assessed at week 0 (baseline) and week 8 using the 15-item, self-administered International Index of Erectile Function (IIEF). Responses were graded from 0 (did not attempt intercourse) or 1 (almost never/never) to 5 (almost always/always). Responders in this analysis were defined as patients reaching a final (end-of-treatment) score of > 1 from baseline CONCLUSIONS: The results of this meta-analysis indicate that sildenafil, at doses of 50 and 100 mg, is effective in men with severe ED, with response rates ranging from 46% to 73%.